Financials in USD. Standardized financial statements.
A compact view of how Lumos Pharma, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.05M | $1.52M | $230,000 | $168,000 | $936,000 | $1.21M | $390,000 | $3.53M | $36.14M | $165.95M |
| Revenue Growth? | +34.7% | +562.2% | +36.9% | -82.1% | -22.4% | +209.2% | -88.9% | -90.2% | -78.2% | 0.0% |
| Cost of Revenue? | $0 | $49,000 | $0 | $0 | $37,000 | -$11.27M | $1.41M | $0 | -$32.36M | -$6.64M |
| Gross Profit? | $2.05M | $1.47M | $230,000 | $168,000 | $899,000 | $12.47M | -$1.02M | $3.53M | $68.50M | $172.59M |
| Gross Margin? | +100.0% | +96.8% | +100.0% | +100.0% | +96.0% | +1034.3% | -260.8% | +100.0% | +189.5% | +104.0% |
| Operating Expenses? | $38.66M | $33.56M | $31.58M | $26.47M | $46.07M | $63.64M | $73.27M | $94.28M | $69.75M | $48.38M |
| Operating Income? | -$36.61M | -$32.04M | -$31.35M | -$26.30M | -$45.13M | -$62.44M | -$72.88M | -$90.76M | -$33.60M | $117.57M |
| EBITDA? | -$36.57M | -$31.99M | -$31.13M | -$25.72M | -$9.67M | -$59.37M | -$70.98M | -$88.41M | -$31.95M | $118.76M |
| Income Before Tax | -$34.06M | -$31.07M | -$31.07M | -$19.64M | -$42.98M | -$60.56M | -$72.51M | -$90.51M | -$33.64M | $117.63M |
| Income Tax Expense | -$29,000 | -$13,000 | -$636,000 | -$13.97M | $12,000 | -$6.97M | -$559,000 | -$5.36M | $6.74M | $14.78M |
| Net Income? | -$34.03M | -$31.06M | -$30.43M | -$5.66M | -$42.99M | -$53.59M | -$71.95M | -$85.16M | -$40.38M | $102.86M |
| EPS? | $-4.18 | $-3.71 | $-3.65 | $-0.84 | $-10.39 | $-12.97 | $-20.69 | $-26.45 | $-12.71 | $31.05 |
| Diluted EPS? | $-4.18 | $-3.71 | $-3.65 | $-0.84 | $-10.39 | $-12.97 | $-20.69 | $-26.45 | $-12.71 | $27.81 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality